Atopic Dermatitis

Experts discuss game-changing drugs and what’s in the pipeline.

Experts share clinical insights boxed warning for the JAK inhibitor drug class.

Raj Chovatiya, MD, PhD, and Lisa Swanson, MD, FAAD, explore the burden of itch in atopic dermatitis, and why JAK inhibitors may be able to provide relief.

In this episode, Bernard Cohen, MD, professor of pediatrics and dermatology at Johns Hopkins University School of Medicine, talks about how physicians and patients should treat atopic dermatitis in the winter months, and some new data on treating newborns.

Dermavant announced positive results from its pediatric maximal usage study.

BLA submission is based on phase 3 trial results evaluating the safety and efficacy of lebrikizumab.

Brexogen Inc.’s exosome therapy is the first entry of a clinical trial of exosome treatment for atopic dermatitis.

Raj Chovatiya, MD, PhD, and Lisa Swanson, MD, FAAD, talk about the use of oral systemic agents and what they’ve learned about the patient experience from the use of these agents.

Raj Chovatiya, MD, PhD, and Lisa Swanson, MD, FAAD, examine the clinical context for the approval of topical ruxolitinib and its role in the treatment armamentarium.

Recent studies show patients are experiencing adverse effects of stopping corticosteroid treatment.

Thought leaders discuss why JAK inhibitors are well suited for the management of itch and inflammation in the treatment of moderate to severe atopic dermatitis.

Raj Chovatiya, MD, PhD, and Lisa Swanson, MD, FAAD, review the recent trajectory of the atopic dermatitis therapeutic spectrum, notably how several newer approvals have changed how clinicians approach treatment.

At the 2022 Fall Clinical Dermatology Conference, one clinician discusses history, definitions, and diagnosis for this common skin affliction.

Lisa Swanson, MD, FAAD, and James Q. Del Rosso, DO, FAOCD, FAAD, gave an in-depth discussion on Janus kinase (JAK) inhibitors for the management of atopic dermatitis at the 2022 Fall Clinical Dermatology Conference.

Alphyn Biologics’ study of AB-101a also evaluates patients who suffer from bacterial infections associated with atopic dermatitis.

In this episode, Jeffrey M. Cohen, MD, a board-certified medical dermatologist and the director of the Psoriasis Treatment Program at the Yale School of Medicine, discusses treatment options for adolescents with atopic dermatitis, how the changing seasons can affect flare-ups, and what caregivers can do at home to help prevent extreme itching.

A new study shows the AD drug does not interfere with vaccinations or increase severity.

In this week’s Pointers with Dr Portela, the 208SkinDoc discusses holistic medicine vs. western medicine for eczema treatment.

A real-world study of children with moderate-to-severe atopic dermatitis (AD) in China found Dupixent can reduce symptoms and improve pruritus. Traditional therapies had little effect, according to the researchers.

Recent study results demonstrated a noticeable reduction in itch just 12 hours after application of ruxolitinib.

The CHMP's recommendations are based on data from a phase 3 ECZTRA 6 trial in adolescents with moderate-to-severe AD cases.

A national study in Germany identified the baseline characteristics of patients with moderate-to-severe atopic dermatitis (AD) to understand how they are usually treated with Dupixent in the real world.

Dermatology experts discuss atopic dermatitis treatment in skin of color patients in this DermView series recap.

Joshua Zeichner, MD; Brittany Craiglow, MD; Elizabeth Swanson, MD; Vikash Oza, MD; and Raj Chovatiya, MD, PhD, provide take-home messages for dermatologists treating pediatric patients with atopic dermatitis.

Atopic dermatitis specialists discuss how to have a conversation with parents about risks of biologics and how to answer questions about length of therapy.